UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2024

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

 

 


On January 31, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated January 31, 2024


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Nanobiotix S.A.    
  (Registrant)
   
  
Date: January 31, 2024     /s/ Bart Van Rhijn    
  Bart Van Rhijn
  Chief Financial Officer
  
EdgarFiling

EXHIBIT 99.1

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024, at 3:00 PM ET / 9:00 PM CET in New York, NY.

The fireside chat will be webcast live from the events page of the Investors section of the Company’s website. A replay of the webcast will be available following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in, among other, Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 20 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix 

Communications Department

Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com


Investor Relations Department

Craig West
SVP, Investor Relations
+1 (617) 583-0211
investors@nanobiotix.com

 
Media Relations 

FR – Ulysse Communication
Pierre-Louis Germain
+ 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com


Global – LifeSci Advisors
Kevin Gardner
+1 (617) 283-2856
kgardner@lifesciadvisors.com

 

 

Attachment

  • 2024-01-31 -- NBTX -- Presenting @ Guggenheim -- FINAL (https://ml.globenewswire.com/Resource/Download/e33a1bc3-3e46-4d4c-8ee8-14037eca7b25)